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Aims To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left
ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes.
Methods
and results
The 6632 patients of the EPHESUS study were randomized from day 3 to 14 after the index AMI (median ¼ 7 days),
of these 3319 were assigned to eplerenone. We analysed the differential effects of time-to-eplerenone initiation vs.
placebo, based on the median time to initiation of treatment (,7 days—‘earlier’, 7days—‘later’). Effects on out-
comes were evaluated over a mean 16-month follow-up, using Cox proportional hazards regression analysis. The
earlier eplerenone initiation (,7 days) reduced the risk of all-cause mortality by 31% (P ¼ 0.001) when compared
with the ‘earlier’ placebo’ and also reduced the risks of cardiovascular (CV) hospitalization/CV mortality by 24%
(P , 0.0001) and sudden cardiac death (SCD) by 34% (P , 0.0001). In contrast, later eplerenone initiation (7
days) had no significant effect on outcomes. Interactions between time-to-randomization and treatment were signifi-
cant. These associations remained substantially unchanged after risk adjustment in multivariable models.
Conclusion An earlier eplerenone administration (3–7days) post-AMI improved outcomes in patients with LVSD and HF. This
benefit was not observed when eplerenone was initiated later (7days).
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Introduction
Recent evidence suggests that high plasma aldosterone levels from
the first hours to the first days after the onset of acute myocardial
infarction (AMI) and increased transcardiac extraction of aldoster-
one early after AMI are correlated with poor outcomes and
adverse cardiac remodelling.1– 3 It has also been shown that early
aldosterone blockade within 24 h after an AMI may prevent the
post-infarct left ventricular remodelling.4 However, the long-term
effect of early aldosterone blockade in these patients is
unknown. In the Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study (EPHESUS), eplerenone,
a selective aldosterone receptor antagonist, improved outcomes
when initiated 3–14 days after AMI complicated by left ventricular
systolic dysfunction (LVSD) and heart failure (HF) or diabetes.5
However, whether timing of initiation of eplerenone had associ-
ated with outcomes in EPHESUS has not been examined before.
In a preliminary exploratory analysis of the EPHESUS data and
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before proceeding to further analyses, we identified a significant
interaction between time-to-randomization (as a continuous vari-
able) and treatment with respect to the primary endpoint of
death from any cause (P ¼ 0.01). The objective of this study was
to test the hypothesis that an earlier initiation of eplerenone in
patients with AMI complicated by HF and LVSD is associated
with better long-term outcomes.
Methods
Patients and study design
This study is a post hoc analysis of EPHESUS, a multicentre, randomized
double-blind clinical trial of eplerenone after AMI. The design and
primary results of EPHESUS have been published.5,6 Briefly,
EPHESUS enrolled 6632 patients with AMI complicated by clinical
HF and LVSD [left ventricular ejection fraction (LVEF) 40%]. Patients
were randomized during a 12-day period (days 3–14) after AMI to
eplerenone (25 mg/day, titrated to 50 mg/day after 4 weeks) or match-
ing placebo. Patients were receiving background therapy with
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor
blockers (ARB), beta-blockers, diuretics, and coronary reperfusion
therapy as indicated.
For the purpose of this analysis, treatment status was categorized
into four groups: (i) placebo ‘earlier’ (,7days); (ii) eplerenone
‘earlier’ (,7days), (iii) placebo ‘later’ (7days), and (iv) eplerenone
‘later’ (7days), based on the median time-to-randomization after
AMI in EPHESUS which was 7 days. Of the 6632 enrolled patients,
1388 received placebo and 1369 received eplerenone ,7 days after
the AMI (from days 3 to 6) and 1925 received placebo and 1950
received eplerenone 7 days after the AMI (from days 7 to 14).
Co-primary endpoints of EPHESUS were all-cause mortality and the
combined endpoint of cardiovascular (CV) hospitalization or CV
death. Cause-specific CV mortalities including sudden cardiac death
(SCD) were evaluated as secondary endpoints. For the present analy-
sis, the co-primary endpoints as well as the secondary endpoint of
SCD were assessed during a mean follow-up of 16 months. All end-
points were adjudicated by a blinded clinical events committee. All
patients randomized in EPHESUS were included in this analysis.
Statistical analysis
Data are reported as mean (SD) for continuous variables and percen-
tages for categorical variables. Continuous variables were analysed by
the Kruskal–Wallis test and categorical variables by the x2 test.
We used Cox proportional hazards models to study the relationship
between the time of eplerenone initiation and all-cause mortality, CV
hospitalization/CV death and SCD, using earlier and later eplerenone
and placebo groups as dummy variables. By taking consecutively,
placebo ‘earlier’, placebo ‘later’, and eplerenone ‘later’ groups as the
reference category we obtained all the clinically relevant comparisons
between the different treatment categories (i.e. placebo ‘earlier’ vs.
eplerenone ‘earlier’, placebo ‘later’ vs. eplerenone ‘later’ and eplere-
none ‘later’ vs. eplerenone ‘earlier’). We then repeated our analysis
using multivariable models to determine the adjusted hazard ratios
(HR) for each treatment category including clinically relevant prognos-
tic variables (age, gender, body mass index, systolic blood pressure,
heart rate, LVEF, Killip class III– IV, atrial fibrillation, serum sodium,
serum potassium, creatinine clearance, prior AMI, prior hospitaliz-
ations for HF, diabetes, history of hypertension, smoking, history of
angina, ACE-inhibitor or ARB, beta-blockers, diuretics, aspirin,
statins, digitalis, potassium supplements, reperfusion/revascularization).
We determined that the assumption of proportional hazards was met
in all Cox models. Time-to-event distributions were summarized using
Kaplan–Meier survival curves. We report unadjusted and adjusted HR
and corresponding 95% confidence intervals (CI) for the treatment
variable. We do not present full models, because we did not aim to
develop a risk stratification tool but rather to determine the extent
to which the timing of treatment initiation altered outcomes and gen-
erate a hypothesis. The existence of an interaction between
time-to-randomization and treatment was evaluated for each endpoint
with use of a Cox model incorporating terms for treatment,
time-to-randomization and interaction between treatment and
time-to-randomization. For these analyses, time-to-randomization
was initially considered as a continuous variable (in our preliminary
explorative analysis) and then as a binary variable dichotomized at
the median value. We then performed a subgroup sensitivity analysis
in separate cohorts of propensity score-matched ‘earlier’ and ‘later’
patients. Among each group, we estimated propensity score for epler-
enone use based on 65 baseline characteristics, and then assembled
1184 pairs of propensity-matched earlier eplerenone and placebo
patients and 1739 pairs of propensity-matched later eplerenone and
placebo patients. Matched Cox regression analyses were used to esti-
mate the effect of eplerenone vs. placebo, separately within matched
earlier and later patients.
Statistical tests were two-tailed and a P-value less than 0.05 was
taken as the level of significance.
Results
Patient characteristics
Baseline characteristics of patients by treatment and time-to-
randomization are displayed in Table 1. Patients had a mean age
of 64 years, about three-quarters were men, a third had diabetes,
and a quarter had a prior AMI. Most patients were receiving back-
ground therapy with ACE-inhibitor, ARB, and beta-blockers. In
general, patients who were randomized ‘later’ were more likely
to have worse renal function and were less likely to receive revas-
cularization, ACE-inhibitors, beta-blockers, aspirin, and statins.
Event rates
Crude rates of death and hospitalization for placebo, eplerenone
‘earlier’ and eplerenone ‘later’ groups are displayed in Table 2.
Patients assigned earlier to eplerenone had significantly lower
event rates when compared with ‘earlier’ placebo patients for all-
cause mortality (11.5 vs. 16.1%), CV hospitalization/CV mortality
(24 vs. 30.3%), and SCD (3.7 vs. 6.9%). No significant differences
were found between ‘later’ eplerenone patients and their
placebo comparators regarding the crude rates of outcomes.
Timing of treatment initiation and risk
Unadjusted and adjusted HR according to the time of eplerenone
initiation (vs. placebo) are reported in Table 3. Earlier eplerenone
administration (,7 days) when compared with ‘earlier’ placebo
was associated with significant unadjusted reduction of risk with
respect to all endpoints (Figure 1A–C). Even after adjustment for
other risk factors, earlier eplerenone initiation substantially
reduced the risk of all-cause mortality (HR: 0.72; 95% CI: 0.58–
0.89; P ¼ 0.002), CV hospitalization/CV mortality (HR: 0.78;
95% CI: 0.67–0.90; P ¼ 0.001), and SCD (HR: 0.54; 95%
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CI: 0.38–0.77; P ¼ 0.001). In contrast, later eplerenone initiation
(7 days) was not associated with unadjusted or adjusted
reduction of risk for any of the endpoints. In a head-to-head
comparison between the two eplerenone groups, ‘earlier’ eplere-
none administration was associated with significantly lower risk
(unadjusted and adjusted) with respect to all endpoints (Table 3).
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Table 1 Baseline characteristics by time-to-randomization and treatment group











Age (years) 63.9+11.9 64.3+11.5 63.1+11.5 64.2+11.1 0.01
Male 73 68 75 70 ,0.0001
Body mass index (kg/m2) 27.3+4.4 27.1+4.4 27.5+4.7 27.5+4.4 NS
Systolic blood pressure (mmHg) 119+16 118+16 120+17 119+16 NS
Diastolic blood pressure (mmHg) 71+10 72+10 72+11 72+11 NS
Heart rate (b.p.m.) 75+12 74+11 76+12 74+12 ,0.0001
LVEF (%) 33+6 33+6 33+6 33+6 NS
Heart failure symptoms (Killip .1) 84 85 85 85 NS
Killip class III– IV 17 22 18 21 0.05
Atrial fibrillation at entry 9 12 9 11 0.05
Serum potassium (mmol/L) 4.17+0.42 4.32+0.45 4.17+0.42 4.35+0.44 ,0.0001
Serum sodium (mmol/L) 139+4 139+4 139+4 139+5 0.05
Serum creatinine (mmol/L) 98+28 100+30 99+28 100+29 0.02
Creatinine clearance (mL/min)b 80+34 75+31 81+35 76+31 ,0.0001
Medical history
Prior AMI 29 26 27 28 NS
Prior heart failure hospitalizations 8 8 7 7 NS
Diabetes mellitus 32 32 32 32 NS
Hypertension 60 62 58 61 NS
Smoking 61 60 65 59 0.01
Angina 39 42 39 44 0.02
Baseline treatmentc
ACE-I or ARB 90 86 90 84 ,0.0001
Beta-blocker 79 72 80 72 ,0.0001
Diuretics 61 60 60 59 NS
Potassium supplements 20 15 19 14 ,0.0001
Digitalis 14 16 13 16 0.025
Aspirin 92 87 90 86 ,0.0001
Statins 52 43 53 42 ,0.0001
Reperfusion/revascularization 51 41 51 41 ,0.0001
AMI, acute myocardial infarction; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVEF, left ventricular ejection fraction.
aP-values denote differences between groups.
bCreatinine clearance was calculated according to Cockroft–Gault formula.
cData for treatment taken at randomization or up to 14 days after the index acute myocardial infarction (AMI).
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Table 2 Crude rates of death and hospitalization according to treatment assignment













All-cause mortality, n (%) 224 (16.1%) 157 (11.5%) ,0.0001 330 (17.1%) 321 (16.5%) NS
Death from CV causes or
hospitalization for CV
events, n (%)
420 (30.3%) 329 (24%) ,0.0001 573 (29.8%) 556 (28.5%) NS
Sudden cardiac death, n (%) 96 (6.9%) 51 (3.7%) ,0.0001 105 (5.5%) 111 (5.7%) NS
aP-values indicate differences between each eplerenone group vs. the corresponding placebo group.
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Finally, no significant difference was found in a direct comparison




In our preliminary explorative analysis, interaction between
time-to-randomization (as continuous variable) and treatment
was significant (P ¼ 0.01) with respect to the primary endpoint
of mortality due to any cause. Subsequent interaction tests
between time-to-randomization (as binary variable) and treatment
were significant for the three endpoints of this analysis and are
summarized in Table 3.
Propensity-matched analysis
In the earlier randomized subgroup (,7 days), among the 1184
pairs of propensity-matched patients, death from any cause
occurred in 11.1 and 15.4% of eplerenone and placebo patients,
respectively (matched HR: 0.65; 95% CI: 0.51–0.83; P , 0.0001).
However, in the later randomized subgroup (7 days), among
the 1739 pairs of matched patients, death from any cause occurred
in 16.3 and 16.7% of eplerenone and placebo patients, respectively
(matched HR: 1.04; 95% CI: 0.87–1.25; P ¼ 0.65).
Safety of earlier eplerenone therapy
Earlier eplerenone initiation was not associated with an excess of
serious adverse events. The incidence of hypotension (systolic
blood pressure ,90 mmHg) in the eplerenone ‘earlier’ group
was low (2.6%), and there was no significant difference in the inci-
dence of hypotension between the eplerenone ‘earlier’, eplere-
none ‘later’, and placebo groups. The incidence of serious
hyperkalaemia (serum potassium increase above 6 mmol/L) was
low (1% in all groups) and did not differ between groups.
Finally, the incidence of serum creatinine increase above 133 and
220 mmol/L was 3.1 and 0.6%, respectively, for the eplerenone
‘earlier’ patients and did not differ significantly between the treat-
ment groups. Study adverse events have been reported at any visit
from baseline to week 4.
Discussion
This post hoc analysis of the EPHESUS trial suggests that earlier
eplerenone initiation, ,7 days post-AMI complicated by LVSD
and HF, was safe and associated with a significant reduction in
the primary endpoint of all-cause mortality and the co-primary
endpoint of CV hospitalization or CV mortality. Further, the
benefit was extended to a profound reduction in SCD, an impor-
tant cause of mortality in these patients. In contrast, these benefits
were not observed when eplerenone therapy was initiated later
(7 days or more) in the post-AMI period. Patients in this study
were already receiving ‘optimal’ therapy including ACE-inhibitors
or ARB, beta-blockers, aspirin, and coronary reperfusion. The sub-
group propensity-matched analysis confirmed the results of our
global analysis.
Aldosterone plasma levels and transcardiac extraction of aldos-
terone may be increased from the first hours to the first days after
an AMI and are associated with adverse cardiac remodelling and
poor prognosis.1– 3 Furthermore, early aldosterone blockade
within 24 h post-AMI may prevent post-infarct left ventricular
remodelling and fibrosis.4 These findings provide a plausible expla-
nation for the improved outcomes of the earlier eplerenone
administration in our study. Data from animal studies suggest
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Table 3 Risk of death and hospitalization according to time of eplerenone initiation






Unadjusted hazard ratio (95% CI)
Placebo ‘earlier’ vs. eplerenone
‘earlier’
0.69 (0.57–0.85) 0.001 0.76 (0.66–0.88) ,0.0001 0.66 (0.55–0.80) ,0.0001
Placebo ‘later’ vs. eplerenone
‘later’
0.94 (0.80–1.10) 0.45 0.94 (0.84–1.05) 0.30 1.02 (0.78–1.33) 0.85
Eplerenone ‘later’ vs. eplerenone
‘earlier’
0.66 (0.55–0.80) ,0.0001 0.81 (0.70–0.92) 0.002 0.62 (0.44–0.87) 0.006
Adjusted hazard ratio (95% CI)
Placebo ‘earlier’ vs. eplerenone
‘earlier’
0.72 (0.58–0.89) 0.002 0.78 (0.67–0.90) 0.001 0.54 (0.38–0.77) 0.001
Placebo ‘later’ vs. eplerenone
‘later’
0.93 (0.79–1.09) 0.37 0.94 (0.83–1.06) 0.32 1.01 (0.77–1.33) 0.91
Eplerenone ‘later’ vs. eplerenone
‘earlier’





CV, cardiovascular; CI, confidence interval.
aThe first group in each comparison indicates the reference group (hazard ratio ¼ 1).
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that aldosterone antagonism may prevent early electrical remodel-
ling that precedes cellular hypertrophy, arrhythmias, and sudden
death post-AMI. The same data also showed that these early
changes can be prevented by blockade of mineralocorticoid recep-
tors.7 Thus, the protective effect of eplerenone against SCD may
be due to its effects on acute electrical remodelling rather than
to chronic ventricular remodelling. In addition, it has been shown
that eplerenone may prevent restenosis in laboratory animals
when administered early at the time of the angioplasty,8 and that
aldosterone-blocking agents also have anti-thrombotic proper-
ties.9 – 11 Finally, it has been recently reported that aldosterone
blockade when administered early post-experimental AMI,
results in enhanced infarct neovascularization, improved infarct
healing and reduced ventricular dilation and dysfunction.12
Clinical implications
Patients with AMI who develop systolic HF are a high-risk popu-
lation with increased risk of in-hospital and post-discharge mor-
tality.13 –16 Early eplerenone initiation was associated with an
additional mortality benefit above that provided by other estab-
lished therapies for AMI. Other established therapies for AMI
such as aspirin, ACE-inhibitors, coronary reperfusion, beta-
blockers, and statins also seem to be most effective when initiated
early after AMI.17– 21 Therefore, our data suggest that aldosterone
blockade should not be delayed after AMI and that eplerenone
may be initiated as early as 3 days after an AMI along with these
other drugs. This is important, as risk reduction with eplerenone
seemed to occur as early as 10 days after randomization22 and
also because patients receiving these drugs are more likely to
benefit from eplerenone.5 It is possible that initiation of eplere-
none during the first 2 days after AMI might result in further mor-
tality reduction and possibly before 10 days after initiation of
therapy. Whether eplerenone can be initiated sooner than
3 days is currently unknown and will need to be prospectively
determined in future randomized clinical trials. The risk of SCD
is the highest in the first 30 days after myocardial infarction.23 In
contrast to eplerenone’s effects on reducing SCD and all-cause
death when administered during the early post-AMI period,
implantable cardioverter defibrillators have not been shown to
reduce all-cause mortality when placed early post-MI. Although
with implantable cardioverter defibrillators a significant decrease
in arrhythmic death was observed, the rate of non-arrhythmic
death was significantly increased.24
Finally, an early initiation of eplerenone in the hospital setting
will also ensure that patients are discharged on this drug. This is
important as the mean length of stay for AMI is decreasing25 and
patients often do not receive new medications after hospital
discharge.26,27
In this analysis, the lack of a statistically significant improvement
in outcomes in the ‘later’ eplerenone group is seemingly contradic-
tory with the results of the previously published RALES trial28
which showed an important reduction in mortality in patients
with chronic severe HF who received anti-aldosterone therapy.
However, whereas the RALES trial enrolled patients with long-
standing HF prior to initiation of the anti-aldosterone treatment,
our EPHESUS ‘later’ group represents a late stage of a rapidly pro-
gressive acute event (AMI). Consequently, the major differences in
the enrolled population in these two trials may explain the differ-
ential effect of the anti-aldosterone treatment. Another plausible
explanation is that the mortality benefit in our analysis is largely
driven by a striking reduction in SCD. This observation suggests
that the protective effect of the anti-aldosterone therapy early in
Figure 1 Kaplan–Meier estimates of the rate of all-cause mor-
tality (A), the rate of death from cardiovascular causes or cardio-
vascular hospitalization for cardiovascular events (B), and the rate
of sudden cardiac death (C).
Earlier post-AMI eplerenone initiation in patients with LVSD and HF 1103
the setting of an AMI may be predominantly due to its actions on
early electrical remodelling rather than to its actions on chronic
ventricular remodelling as may be the case in chronic HF.
Safety of early eplerenone therapy
Eplerenone was well tolerated in the early as well as the late sub-
group. There were no major haemodynamic or biochemical
adverse effects. Although aldosterone blockade early after AMI
may potentially affect collagen formation and thus interfere with
the healing of the infarct zone and increase the risk for aneurysm
formation and/or cardiac rupture, Delyani et al.29 have shown in an
experimental model that aldosterone receptor antagonism does
not retard infarct healing. In our analysis, the eplerenone-
associated significant reduction in sudden and death from any
cause suggests that the overall effect of eplerenone was beneficial.
Limitations
This study is a post hoc, hypothesis-generating analysis and the
results should be interpreted with caution; patients were not ran-
domized to ‘earlier’ or ‘later’ eplerenone treatment and the broad
time window for entry into EPHESUS (3–14 days from the index
AMI) may have resulted in a heterogeneous enrolled population;
patients in these two groups represented the two spectrums of
an acutely evolving process where insults or interventions in the
early stage may affect prognosis later in the course. Despite adjust-
ment for the confounding factors, causality cannot be definitively
established based on these data.
Patients were randomized in EPHESUS between 3 and 14 days
after AMI. Thus, we cannot evaluate whether these findings also
apply to earlier timepoints (i.e. prior to 3 days).
Notwithstanding the lack of a statistically significant improve-
ment in outcomes in the ‘later’ eplerenone group, a benefit of a
later initiation of eplerenone cannot be completely excluded on
the basis of this analysis alone. It remains possible that clinical
benefits from later eplerenone initiation, though present, are
inconsequential in magnitude and do not favourably impact on
the overall prognosis of this patient population. However, the
present data suggest that the effect of eplerenone is most robust
when initiated early in the post-MI period.
Conclusion
Early eplerenone initiation (,7 days) in post-AMI patients with
systolic HF and receiving baseline optimal therapy was safe and
was associated with a statistically significant lower rate of all-cause
mortality, CV hospitalization or CV death, and SCD when com-
pared with placebo. In contrast, no significant differences in out-
comes were observed for later initiation. These findings provide
important insight with regard to the optimal timing for eplerenone
initiation to ensure maximum clinical benefits are achieved. Pro-
spective randomized clinical trials are needed to determine
whether eplerenone initiated even earlier in the AMI setting (,3
days) would be effective at further improving patient outcomes.
Acknowledgements
The authors acknowledge the EPHESUS investigators for their
contributions to the EPHESUS study.
Conflict of interest: J.V. is a Pfizer employee, B.P. and F.Z. are
consultants to Pfizer. Other authors have no other disclosures
to declare.
Funding
The EPHESUS trial was funded by Pfizer, Inc.
References
1. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O,
Montalescot G. High plasma aldosterone levels on admission are associated
with death in patients presenting with acute ST-elevation myocardial infarction.
Circulation 2006;114:2604–2610.
2. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Matsui T,
Fujii M, Matsumoto T, Yamamoto T, Horie H, Ohnishi M, Kinoshita M. Relation-
ship between transcardiac extraction of aldosterone and left ventricular remodel-
ing in patients with first acute myocardial infarction: extracting aldosterone
through the heart promotes ventricular remodeling after acute myocardial infarc-
tion. J Am Coll Cardiol 2001;38:1375–1382.
3. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG,
Richards AM. Plasma aldosterone levels during hospitalization are predictive of
survival post-myocardial infarction. Eur Heart J 2008;29:2489–2496.
4. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A,
Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M.
Immediate administration of mineralocorticoid receptor antagonist spironolac-
tone prevents post-infarct left ventricular remodeling associated with suppression
of a marker of myocardial collagen synthesis in patients with first anterior acute
myocardial infarction. Circulation 2003;107:2559–2565.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S,
Kleiman J, Gatlin M. Eplerenone a selective aldosterone blocker in patients with
left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:
1309–1321.
6. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J,
Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplere-
none in patients with heart failure due to systolic dysfunction complicating
acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Sur-
vival Study. Cardiovasc Drugs Ther 2001;15:79–87.
7. Perrier E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S, Gomez AM,
Benitah JP. Mineralocorticoid receptor antagonism prevents the electrical remo-
deling that precedes cellular hypertrophy after myocardial infarction. Circulation
2004;110:776–783.
8. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses con-
strictive remodeling and collagen accumulation after angioplasty in porcine coron-
ary arteries. Circulation 2001;104:467–472.
9. Chun TY, Pratt JH. Aldosterone increases plasminogen activator inhibitor-1 syn-
thesis in rat cardiomyocytes. Mol Cell Endocrinol 2005;239:55–61.
10. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the
relationship between aldosterone and plasminogen activator inhibitor-1 in
humans. J Clin Endocrinol Metab 2002;87:448–452.
11. Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ. Effect of com-
bined AT1 receptor and aldosterone receptor antagonism on plasminogen activa-
tor inhibitor-1. J Clin Endocrinol Metab 2003;88:3867–3873.
12. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G, Bauersachs J.
Immediate mineralocorticoid receptor blockade improves myocardial infarct
healing by modulation of the inflammatory response. Hypertension 2008;51:
905–914.
13. Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, Ohman EM,
Granger CB, Van de Werf F, Simoons ML, O’Connor C M, Holmes DR Jr. Fre-
quency, patient characteristics, and outcomes of mild-to-moderate heart failure
complicating ST-segment elevation acute myocardial infarction: lessons from 4
international fibrinolytic therapy trials. Am Heart J 2003;145:73–79.
14. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J,
Budaj A, Goldberg RJ, Klein W, Anderson FA Jr. Determinants and prognostic
impact of heart failure complicating acute coronary syndromes: observations
from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004;
109:494–499.
15. Velazquez EJ, Francis GS, Armstrong PW, Aylward PE, Diaz R, O’Connor CM,
White HD, Henis M, Rittenhouse LM, Kilaru R, van Gilst W, Ertl G,
Maggioni AP, Spac J, Weaver WD, Rouleau JL, McMurray JJ, Pfeffer MA,
Califf RM. An international perspective on heart failure and left ventricular systolic
dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J
2004;25:1911–1919.
16. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting
with congestive heart failure complicating acute myocardial infarction: a report
C. Adamopoulos et al.1104
from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll
Cardiol 2002;40:1389–1394.
17. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3:
effects of lisinopril transdermal glyceryl trinitrate singly together on 6-week mortality
ventricular function after acute myocardial infarction. Lancet 1994;343:1115–1122.
18. Ambrosioni E, Borghi C, Magnani B The Survival of Myocardial Infarction Long-
Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-
converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior
myocardial infarction. N Engl J Med 1995;332:80–85.
19. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of cor-
onary heart disease by implementation of a Cardiac Hospitalization Atherosclero-
sis Management Program (CHAMP). Am J Cardiol 2001;87:819–822.
20. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of
angiotensin-converting enzyme inhibitors on mortality after myocardial infarction.
Am J Med 2003;115:473–479.
21. Rogers WJ, Bourge RC, Papapietro SE, Wackers FJ, Zaret BL, Forman S, Dodge HT,
Robertson TL, Passamani ER, Braunwald E, for the TIMI Investigators. Variables
predictive of good functional outcome following thrombolytic therapy in the
Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study. Am J Cardiol
1989;63:503–512.
22. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van
Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J. Eplerenone reduces
mortality 30 days after randomization following acute myocardial infarction in
patients with left ventricular systolic dysfunction and heart failure. J Am Coll
Cardiol 2005;46:425–431.
23. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G,
Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F,
Pieper K, Califf RM, Pfeffer MA. Sudden death in patients with myocardial infarc-
tion and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:
2581–2588.
24. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E,
Gent M, Connolly SJ. Prophylactic use of an implantable cardioverter-defibrillator
after acute myocardial infarction. N Engl J Med 2004;351:2481–2488.
25. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL,
Krumholz HM. Most hospitalized older persons do not meet the enrollment cri-
teria for clinical trials in heart failure. Am Heart J 2003;146:250–257.
26. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR. Out-
patient adherence to beta-blocker therapy after acute myocardial infarction. J Am
Coll Cardiol 2002;40:1589–1595.
27. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient util-
ization of angiotensin-converting enzyme inhibitors among heart failure patients
after hospital discharge. J Am Coll Cardiol 2004;43:2036–2043.
28. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J
Randomized Aldactone Evaluation Study Investigators. The effect of spironolac-
tone on morbidity and mortality in patients with severe heart failure. N Engl J
Med 1999;341:709–717.
29. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor
antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:
H647–H654.
Earlier post-AMI eplerenone initiation in patients with LVSD and HF 1105
